U.S. High Court Won’t Review Dismissal Of Abilify Off-Label Qui Tam Lawsuit
WASHINGTON, D.C. — The U.S. Supreme Court on May 29 denied review of the dismissal of a false claims/kickback lawsuit alleging off-labeling marketing of the antipsychotic drug Abilify (United States of...To view the full article, register now.
Already a subscriber? Click here to view full article